Literature DB >> 8080899

Voluntary control of saccadic eye movement in patients with frontal cortical lesions and parkinsonian patients in comparison with that in schizophrenics.

J Fukushima1, K Fukushima, K Miyasaka, I Yamashita.   

Abstract

To investigate whether the abnormalities of antisaccades in schizophrenics could be explained by a dysfunction of the frontal cortex, we examined 10 patients with frontal cortical lesions and 22 patients with idiopathic Parkinson's disease with mild symptoms (Yahr I-II) using the same tasks, and compared the results with those obtained in schizophrenics. The frontal patients with lesions covering the frontal eye field and prefrontal cortex showed more errors, longer latencies, and lower peak velocities in the antisaccade task, despite giving normal results in the visually guided saccade task. This was similar to the results observed in schizophrenics. Parkinsonian patients did not consistently show a significant difference in the antisaccade task. These results indicate specific abnormalities of antisaccades in schizophrenics and patients with frontal cortical lesions but not consistently in Parkinsonian patients. This suggests that the abnormalities of antisaccades in schizophrenics might be explained by a frontal cortical dysfunction.

Entities:  

Mesh:

Year:  1994        PMID: 8080899     DOI: 10.1016/0006-3223(94)90058-2

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  35 in total

1.  Suppression of reflexive saccades in younger and older adults: age comparisons on an antisaccade task.

Authors:  K M Butler; R T Zacks; J M Henderson
Journal:  Mem Cognit       Date:  1999-07

Review 2.  The role of prefrontal cortex in working-memory capacity, executive attention, and general fluid intelligence: an individual-differences perspective.

Authors:  Michael J Kane; Randall W Engle
Journal:  Psychon Bull Rev       Date:  2002-12

3.  The antisaccade task and neuropsychological tests of prefrontal cortical integrity in schizophrenia: empirical findings and interpretative considerations.

Authors:  Deborah L Levy; Nancy R Mendell; Philip S Holzman
Journal:  World Psychiatry       Date:  2004-02       Impact factor: 49.548

4.  Deficient saccadic inhibition in Asperger's disorder and the social-emotional processing disorder.

Authors:  D S Manoach; K A Lindgren; J J S Barton
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-12       Impact factor: 10.154

5.  Disturbed striatoprefrontal mediated visual behaviour in moderate to severe parkinsonian patients.

Authors:  L Crevits; K De Ridder
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-09       Impact factor: 10.154

6.  The relationship of saccadic peak velocity to latency: evidence for a new prosaccadic abnormality in schizophrenia.

Authors:  Rajeev S Ramchandran; Dara S Manoach; Mariya V Cherkasova; Kristen A Lindgren; Donald C Goff; Jason J S Barton
Journal:  Exp Brain Res       Date:  2004-07-29       Impact factor: 1.972

7.  A double-blind placebo-controlled experimental study of nicotine: II--Effects on response inhibition and executive functioning.

Authors:  Lynne Dawkins; Jane H Powell; Robert West; John Powell; Alan Pickering
Journal:  Psychopharmacology (Berl)       Date:  2007-01-05       Impact factor: 4.530

Review 8.  The tell-tale tasks: a review of saccadic research in psychiatric patient populations.

Authors:  Diane C Gooding; Michele A Basso
Journal:  Brain Cogn       Date:  2008-10-23       Impact factor: 2.310

9.  Components of visual search in childhood-onset schizophrenia and attention-deficit/hyperactivity disorder.

Authors:  C Karatekin; R F Asarnow
Journal:  J Abnorm Child Psychol       Date:  1998-10

10.  Catechol-O-methyltransferase Val 158 Met polymorphism and antisaccade eye movements in schizophrenia.

Authors:  Haraldur Magnus Haraldsson; Ulrich Ettinger; Brynja B Magnusdottir; Thordur Sigmundsson; Engilbert Sigurdsson; Andres Ingason; Hannes Petursson
Journal:  Schizophr Bull       Date:  2008-06-17       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.